Sign In
Buy ALBO
$44.15
+0 (+0%)
At Close: May 26, 2023
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021
08:30am, Friday, 15'th Oct 2021
– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases –
Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan
08:30am, Tuesday, 12'th Oct 2021
– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia –
Albireo Recognizes PFIC Awareness Day 2021
08:30am, Tuesday, 05'th Oct 2021
BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, joins the PFIC Advocacy and Resource Networ
Albireo Announces Bylvay® (odevixibat) Now Available in Germany
08:30am, Wednesday, 15'th Sep 2021
– Listed on the German national price list and all pharmacy software programs –
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Wednesday, 08'th Sep 2021
BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement st
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)
08:30am, Wednesday, 08'th Sep 2021
– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –
Albireo Pharma Sells Bylvay-Associated PRV For $105M
11:04am, Tuesday, 07'th Sep 2021
Albireo Pharma Inc (NASDAQ: ALBO) has agreed to sell its Priority Review Voucher (PRV) for $105 million. The FDA granted the PRV for Bylvay to treat pruritus in all types of progressive familial
Albireo to Present at Upcoming Investor Conferences
08:30am, Thursday, 02'nd Sep 2021
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President
Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
03:13pm, Tuesday, 24'th Aug 2021
Mirum And Maralixibat In Pediatric Cholestasis: The Differentiation
Albireo and Genpharm Announce Agreement to Commercialize Bylvay™ (odevixibat) in Saudi Arabia and the Gulf Region
01:30am, Wednesday, 18'th Aug 2021
– Bylvay is approved in the U.S. and EU as only once-daily drug indicated for patients with PFIC –
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2021 Results - Earnings Call Transcript
06:13pm, Saturday, 07'th Aug 2021
Albireo Pharma, Inc. (ALBO) CEO Ron Cooper on Q2 2021 Results - Earnings Call Transcript
Albireo Reports Q2 Financial Results and Business Update
08:30am, Thursday, 05'th Aug 2021
– Bylvay TM (odevixibat) approved in U.S. & EU as o nly once-daily drug indicated for patients with PFIC –
Albireo to Present at the 2021 Wedbush PacGrow Virtual Healthcare Conference
08:30am, Tuesday, 03'rd Aug 2021
BOSTON, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced that Ron Cooper, President and Chief
Albireo to Report Second Quarter 2021 Financial Results on August 5
08:30am, Thursday, 29'th Jul 2021
— Conference call and webcast to be held at 10:00 a.m. ET — — Conference call and webcast to be held at 10:00 a.m. ET —
Albireo (ALBO) Gets FDA Nod for Rare Liver Disease Drug
12:23pm, Wednesday, 21'st Jul 2021
Following FDA approval, Albireo's (ALBO) Bylvay becomes the first drug to treat pruritus in PFIC.
